BiosyentBIOYF +4.06%98 Pretax Margin % is 23.62% as of Mar. 2026, which is 15% below its 10-year median of 27.93. GuruFocus rates BIOYF with a GF Score™ of 98/100 and a GF Value™ of $11.25 (Fairly Valued). The stock has 4 warning signs investors should review. Among 952 Drug Manufacturers companies, Biosyent ranks better than 89.29% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Biosyent's Pre-Tax Income for the
three
months ended in Mar. 2026 was $2.39 Mil. Biosyent's Revenue for the
three
months ended in Mar. 2026 was $10.14 Mil. Therefore, Biosyent's pretax margin for the quarter that ended in Mar. 2026 was 23.62%.
The historical rank and industry rank for Biosyent's Pretax Margin % or its related term are showing as below:
BIOYF'
s Pretax Margin % Range Over the Past 10 Years
Min: 23.45 Med: 27.93 Max: 35.06
Current: 26.44
BIOYF's Pretax Margin % is ranked better than 89.29% of 952
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs BIOYF: 26.44
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Biosyent Pretax Margin % Related Terms
Biosyent Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Biosyent's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosyent Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biosyent's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Biosyent's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosyent (BIOYF) has a Pretax Margin % of 23.62% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Biosyent and its competitors. This is 15% below median its historical median of 27.93. Over the past decade, Biosyent's Pretax Margin % has ranged from 23.45 to 35.06. According to the industry distribution chart, Biosyent ranks #102 out of 952 companies in the Drug Manufacturers industry, placing it in the top 10.7%.
Is Biosyent's Pretax Margin % too high?
Biosyent's current Pretax Margin % of 23.62% is 15% below median its 10-year median of 27.93. Over the past 10 years, this metric has ranged from a low of 23.45 to a high of 35.06. The Drug Manufacturers industry median Pretax Margin % is 7.30. Biosyent's value of 23.62% is 223.8% above this industry median. Based on the distribution chart, Biosyent ranks #102 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biosyent has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biosyent's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biosyent ranks #102 out of 952 companies for Pretax Margin %. This places Biosyent in the top 11% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.30. Biosyent's value of 23.62% is 223.8% above this benchmark. Historically, Biosyent's own Pretax Margin % has ranged from 23.45 to 35.06 over the past decade. While the company's 10-year median is 27.93 vs. the industry median of 7.30, Biosyent has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biosyent's current Pretax Margin % of 23.62% is 223.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Biosyent and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosyent's current Pretax Margin % is 23.62%, which is 15% below median its own 10-year median of 27.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosyent stock overvalued right now?
Based on GuruFocus' analysis, Biosyent (BIOYF) is currently considered Fairly Valued. The stock's GF Value™ is $11.25, compared to a current price of $10.26 — trading 8.8% below its estimated fair value. The current Pretax Margin % is 23.62%, which is 15% below median its 10-year median of 27.93 and 223.8% above the Drug Manufacturers industry median of 7.30. Biosyent's overall GF Score™ is 98/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Biosyent (BIOYF), the current Pretax Margin % is 23.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biosyent (BIOYF) Overvalued in 2026?
Based on GuruFocus' analysis, Biosyent stock appears to be undervalued.
The current stock price of $10.26 is trading 8.8% below its estimated GF Value™ of $11.25.
GuruFocus considers Biosyent to be Fairly Valued.
Key valuation signals for BIOYF:
Pretax Margin %: 23.62% (15% below median its 10-year median of 27.93)
GF Value™: $11.25 vs. price of $10.26 (8.8% below fair value)
Industry Position: 223.8% above the Drug Manufacturers median (#102 of 952)
No single metric tells the full story. See the BIOYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
98GF Score
Get the complete analysis for BIOYF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOYF has been successfully added to your 
